Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lorlatinib”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Early research (Phase 1)Study completedNCT02569554
What this trial is testing

PPI And Food Effect Study For PF-06463922 In Healthy Volunteers

Who this might be right for
Healthy
Pfizer 27
Testing effectiveness (Phase 2)UnknownNCT04292119
What this trial is testing

Lorlatinib Combinations in Lung Cancer

Who this might be right for
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more
Massachusetts General Hospital 96
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02584634
What this trial is testing

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 43
Testing effectiveness (Phase 2)Looking for participantsNCT06378892
What this trial is testing

Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Who this might be right for
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT04621188
What this trial is testing

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 54
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Not applicableStudy completedNCT03727477
What this trial is testing

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

Who this might be right for
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Intergroupe Francophone de Cancerologie Thoracique 291
Not applicableActive Not RecruitingNCT07556549
What this trial is testing

Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Who this might be right for
Non-Small Cell Lung Cancer ALK-positive
Pfizer 50
Testing effectiveness (Phase 2)Study completedNCT04111705
What this trial is testing

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 23
Early research (Phase 1)Study completedNCT02804399
What this trial is testing

Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Who this might be right for
Healthy
Pfizer 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05740943
What this trial is testing

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Who this might be right for
Stage III NSCLCSurgery
Guangdong Provincial People's Hospital 48
Not applicableApproved For MarketingNCT03127618
What this trial is testing

Lorlatinib - PF-06463922

Pfizer
Large-scale testing (Phase 3)Looking for participantsNCT03126916
What this trial is testing

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Who this might be right for
GanglioneuroblastomaGanglioneuroblastoma, NodularNeuroblastoma
Children's Oncology Group 750
Testing effectiveness (Phase 2)WithdrawnNCT05948462
What this trial is testing

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
SCRI Development Innovations, LLC
Not applicableActive Not RecruitingNCT06678555
What this trial is testing

Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 35
Not applicableStudy completedNCT06282991
What this trial is testing

Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Who this might be right for
Non-Small Cell Lung Carcinoma
Pfizer 73
Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Early research (Phase 1)Study completedNCT03542305
What this trial is testing

Lorlatinib Renal Impairment Study

Who this might be right for
Renal Impairment
Pfizer 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06682884
What this trial is testing

Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Peking University People's Hospital 25
Load More Results